Paxil CR, Avandamet Seizure Threatens $1 Bil. In Annual Revenue For GSK
Executive Summary
FDA's seizure of GlaxoSmithKline's Paxil CR and Avandamet threatens $1 bil. in annual revenues for the company
You may also be interested in...
GSK Informs Canadian Wholesalers Of Coreg, Paxil, Relafen Shortages
GlaxoSmithKline is informing Canadian pharmacists and wholesalers that it will not be able to fill orders of Coreg, Paxil and Relafen until the end of the year
GSK Informs Canadian Wholesalers Of Coreg, Paxil, Relafen Shortages
GlaxoSmithKline is informing Canadian pharmacists and wholesalers that it will not be able to fill orders of Coreg, Paxil and Relafen until the end of the year
GSK Consent Decree Sets “Aggressive” 150-Day Timeline For GMP Conformity
GlaxoSmithKline's consent decree mandates that the company notify the agency within 150 days of the corrective measures it has taken or plans to take in addressing FDA's good manufacturing practice concerns